Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01222975 · ClinicalTrials.gov registry record · NA
Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fasting Conditions
A NA study, sponsored by Ranbaxy Laboratories Limited.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
NCT01222975: Completed NA study, sponsored by Ranbaxy Laboratories Limited.
NCT01222975 is a NA study that has completed, run by Ranbaxy Laboratories Limited. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01222975, a NA study, has completed, sponsored by Ranbaxy Laboratories Limited.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the pharmacokinetics and bioequivalence of Risperidone formulations after administration of single doses to normal, healthy subjects under fasted conditions.
Interventions
- DRUG Risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2004-10 |
| Est. Completion | 2004-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01222975
The ClinicalTrials.gov registry entry for NCT01222975 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ranbaxy Laboratories Limited, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Risperidone is the first listed.
NCT01222975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01222975 about?
NCT01222975 is a clinical study titled "Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fasting Conditions". The purpose of this study is to determine the pharmacokinetics and bioequivalence of Risperidone formulations after administration of single doses to normal, healthy subjects under fasted conditions.
What is the current status of trial NCT01222975?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2004-10. Estimated completion is 2004-12.
What interventions are being tested in trial NCT01222975?
The interventions under investigation include: Risperidone (DRUG).
Who is sponsoring clinical trial NCT01222975?
This trial is sponsored by Ranbaxy Laboratories Limited, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.